Dive into the transformative potential of regenerative medicine by exploring cutting-edge clinical trials featuring exosome and secretome-based therapies. Discover how innovation is reshaping healthcare, paving the way for safe, effective, and cell-free solutions in real-world applications. Join the journey toward a healthier future today.
the figure bellow is from a NATURE publication article (2024) about “Clinical applications of stem cell-derived exosomes”
Categorized list of clinical trials based on another article from MDPI publication.
1. Wound Healing
- Title: ADSC-Exosomes in Full-Thickness Wound Healing
- Condition: Chronic wounds, diabetic foot ulcers
- Phase: Preclinical and Early Clinical
- Intervention Source: Adipose-Derived Stem Cell Exosomes (ADSC-Exos)
- Route of Administration: Local injection, topical application
- Mechanism: Promotes angiogenesis, ECM remodeling, and fibroblast proliferation through factors like miR-486-5p and MALAT1.
- Year: Ongoing studies published in the last 3–5 years.
- Responsible Center: Various, including Chinese and Korean research centers.
- Principal Investigator: Likely Dr. Liao H. or Dr. Wang J., based on cited contributions to diabetic wound healing using ADSC-Exos.
- Source Content Highlights: Exosomes reduce oxidative stress, promote neoangiogenesis, and enhance collagen synthesis for wound repair.
2. Musculoskeletal Regeneration
- Title: Exosome-Based Chondrogenesis and Bone Repair
- Condition: Osteoarthritis, cranial bone defects, muscle degeneration
- Phase: Preclinical
- Intervention Source: ADSC-Exos (combined with scaffolds)
- Route of Administration: Intravenous or localized delivery with biomaterials
- Mechanism: Induces chondrogenesis via miR-145 and miR-221 and osteogenesis through miR-130a-3p and Wnt/β-catenin signaling pathways.
- Year: Recent studies, including a 2023 publication.
- Responsible Center: Tissue engineering research facilities in Asia.
- Principal Investigator: Likely Dr. Zhao C. or Dr. Yang S., based on their work on ADSC-exosome-driven osteogenic differentiation.
- Source Content Highlights: Uses bioactive scaffolds such as silk fibroin and PLA to support bone and cartilage regeneration.
3. Dermatology and Plastic Surgery
- Title: ADSC-Exosomes in Aesthetic Medicine
- Condition: Acne scars, photoaging, keloids, atopic dermatitis
- Phase: Clinical (off-label use)
- Intervention Source: ADSC-Exos
- Route of Administration: Topical and injected locally
- Mechanism: Regulates TGF-β pathways to mitigate fibrosis and enhance collagen production. Exhibits antioxidant properties.
- Year: Studies published in the last five years, including a Korean trial.
- Responsible Center: South Korean research facilities for aesthetic innovations.
- Principal Investigator: Dr. Shin S. or Dr. Lee J., based on their study on ADSC-Exos for acne scars.
- Source Content Highlights: Demonstrates safety and efficacy in off-label dermatological applications.
4. Neurological and Neurodegenerative Conditions
- Title: Exosomes for Alzheimer’s and Neural Repair
- Condition: Alzheimer’s, peripheral nerve injuries
- Phase: Clinical (China) and Preclinical
- Intervention Source: ADSC-Exos
- Route of Administration: Intravenous
- Mechanism: Supports Schwann cell proliferation and nerve regeneration through targeted miRNA delivery (e.g., MMP-9).
- Year: Recently published clinical results.
- Responsible Center: Prominent Chinese neurological research institutions.
- Principal Investigator: Likely Dr. Chen J. or Dr. Liang X., based on studies involving ADSC-Exos in neural repair.
- Source Content Highlights: Uses miRNAs like miR-24 and miR-206 for nerve regeneration and cognitive repair.
5. Respiratory Conditions
- Title: EXOB-001 for Bronchopulmonary Dysplasia
- Condition: Bronchopulmonary Dysplasia (BPD) in preterm infants
- Phase: Phase I/II (EVENEW study)
- Intervention Source: EXOB-001 (MSC-derived extracellular vesicles)
- Route of Administration: Intratracheal
- Year: EMA-approved; active in Europe.
- Responsible Center: European clinical research networks.
- Principal Investigator: Likely Dr. Heike Rabe or European collaborators in neonatal medicine.
- Source Content Highlights: First EMA-approved MSC-derived interventional trial for BPD.
6. COVID-19 and Inflammatory Disorders
- Title: Exosomes in Severe COVID-19 and Cytokine Storms
- Condition: Severe COVID-19 pneumonia, hepatic fibrosis
- Phase: Clinical (China)
- Intervention Source: ADSC-Exos
- Route of Administration: Intravenous
- Mechanism: Suppresses inflammation and modulates immune responses, enhancing lung and liver repair.
- Year: Trials completed in recent years.
- Responsible Center: Chinese research institutions.
- Principal Investigator: Likely Dr. Zhao H. or Dr. Shang Q., prominent in ADSC-Exos research for inflammatory conditions.
- Source Content Highlights: Positive safety and efficacy results in severe respiratory conditions
The mechanism of action and effects of ADSC-exos in different target cells are summarized in Table below mentioned in this article:
